# Leto Laboratories

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/leto-laboratories

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.letolab.net
- Total disclosed funding: $30M
- Latest round: Series C (Jul 23, 2025)
- Investors on record: 13

## About

Established in 2014 and based in Beijing, China, Leto Laboratories operates as a protein technology and drug developer that providesprotein products, drugs and protein technology platform. The company headquartered in Beijing and its laboratories passed ISO9001:2008 quality system certification. It cooperates with Hansen Pharmaceutical, Tonghua Dongbao and Junshi Biological. Wei Zhang, the CEO and founder of the company, and he once served as the senior research fellow at a leading UK oncology research center and Novo Nordisk. The company provides protein products, drugs and protein technology platform. It develops more than 10 drug discovery platforms, including computer-aided drug design platform, high-throughput protein preparation platform and high-throughput protein screening platform. Its products include refolding, cytokine and peptide drugs. Cytokine can apply in oncology treatment, infection and autoimmune diseases fields. In July 2025, Leto Laboratories closed Series C+ funding from new investor Hankang Capital.

## Funding rounds

- Series C, Jul 23, 2025 — Hankang Capital
- Series C, Dec 31, 2022, $15M — Infinity Group, HB Ventures LLC, Zhongguancun Science City Capital
- Series B, Aug 4, 2021 — China Capital Management
- Series B, Oct 16, 2020, $15M — Qiaojing Capital, Yijing Investment, Changkejin  Investment
- Series A, Jan 25, 2019 — MED-FINE Capital, Qirong Venture Capital, Sherpa Healthcare Partners, Huaige Capital
- Angel, Jul 16, 2018 — Yield Capital, Sherpa Healthcare Partners

## Investors

- Yield Capital (https://capitalatlas.ai/funds/yield-capital) — Angel
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Angel, Series A
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Series A
- Qirong Venture Capital (https://capitalatlas.ai/funds/qirong-venture-capital) — Series A
- Huaige Capital (https://capitalatlas.ai/funds/huaige-capital) — Series A
- Qiaojing Capital (https://capitalatlas.ai/funds/qiaojing-capital) — Series B
- Yijing Investment (https://capitalatlas.ai/funds/yijing-investment) — Series B
- Changkejin  Investment — Series B
- China Capital Management (https://capitalatlas.ai/funds/china-capital-management) — Series B
- Infinity Group (https://capitalatlas.ai/funds/infinity-group) — Series C
- HB Ventures LLC — Series C
- Zhongguancun Science City Capital (https://capitalatlas.ai/funds/zhongguancun-science-city-capital) — Series C
- Hankang Capital (https://capitalatlas.ai/funds/hankang-capital) — Series C